• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Maryland becomes 1st state to pass generic drug price gouging law

June 2, 2017 By Sarah Faulkner

Prescription drugsMaryland is slated to become the 1st state to pass a law banning “price gouging” by generic pharmaceutical manufacturers. The bill was passed by the Maryland general assembly in April and last month the governor said he would allow the bill to become law without his signature.

The bill, which becomes effective on Oct. 1, prohibits generic drug manufacturers and distributors from price gouging in the sale of “an essential off-patent or generic drug”. The law defines price gouging as an “unconscionable increase” or an increase that is “excessive and not justified” by the manufacturing costs associated with expanding access to the drug.

It also includes price increases that result in patients having “no meaningful choice” whether or not to purchase the drug due to insufficient competition in the market.

The bill includes an exemption for wholesale distributors when the price increase is directly linked to additional costs brought on by the manufacturer.

If the wholesale acquisition cost of a prescription drug jumps by at least 50% compared to the previous year, the bill authorizes the Maryland Medical Assistance Program to notify the Maryland attorney general. At that time, the drug manufacturer must justify the price increase within 45 days and the attorney general can seek a court order compelling document disclosure.

In his letter to the speaker of the house, Governor Larry Hogan said that his chief counsel has raised “legal and constitutional concerns” about the bill that were also echoed by generic drug manufacturers in the Association for Accessible Medicines.

The governor pointed out that the law only deals with generic drugs, leaving patented drugs and drug delivery systems, like the EpiPen, untouched. He added that the bill may violate the 14th Amendment’s due process clause due to its vague terms like “unconscionable increase” and “excessive”.

Filed Under: Featured, Legal News, Pharmaceuticals, Wall Street Beat

IN CASE YOU MISSED IT

  • Medtronic enrolls first patient in study for Onyx liquid embolic system
  • BD issues voluntary recall on certain Alaris infusion pump modules
  • Sequel Med Tech expects full twiist launch in the fall
  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS